merakris_logo_4color copy.jpg
Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care
March 12, 2024 06:30 ET | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- A recent multicenter study has demonstrated encouraging effectiveness and safety of Merakris Therapeutics’ Dermacyte® Amniotic Wound...
merakris_logo_4color copy.jpg
Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid
February 20, 2024 06:15 ET | Merakris Therapeutics
Merakris to present encouraging Phase 2 clinical drug trial data at annual Treasure Hunt Podiatry and Wound Conference in Los Angeles, CA, February 24-25.
merakris_logo_4color copy.jpg
Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial
December 05, 2023 06:30 ET | Merakris Therapeutics
Merakris Therapeutics announces it has fully enrolled the first part of a clinical trial to evaluate its investigational drug product, Dermacyte® Liquid.
merakris_logo_4color copy.jpg
Merakris Announces Nationwide At-Your-Door Autologous Serum Tears Program
October 12, 2023 06:30 ET | Merakris Therapeutics
The Opticyte Tears program uses patients’ blood serum to create Autologous Serum Tears from the convenience of their homes.
merakris_logo_4color copy.jpg
Wound Healing Technology Company Merakris Adds Two Executives to Leadership Team
August 15, 2023 06:30 ET | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its...
merakris_logo_4color copy.jpg
Merakris Announces Review in Biomedicines Medical Journal Highlighting Therapeutic Potential of Cell-Free Amniotic Fluid
November 29, 2022 06:15 ET | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- A review published recently in the international scientific journal Biomedicines highlights the therapeutic benefits of amniotic fluid...
merakris_logo_4color copy.jpg
Merakris Sponsored Study Opens Door to Precision-Based Approaches to Wound Healing
September 13, 2022 06:00 ET | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) -- A recently published manuscript containing research sponsored, in part, by Merakris Therapeutics has opened the door to more...
merakris_logo_4color copy.jpg
First Patient Enrolled in Merakris-Sponsored VA Clinical Trial
July 27, 2022 06:30 ET | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- The first patient has been enrolled in a Phase II clinical trial – sponsored by Merakris Therapeutics – to measure the safety and...
merakris_logo_4color copy.jpg
Merakris CEO To Discuss Dermacyte® Development Program As Part of Advanced Wound Care Summit Panel in July
June 28, 2022 08:00 ET | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- About five years ago, the U.S. Food and Drug Administration (FDA) announced plans to toughen its guidelines around the development and...
merakris_logo_4color copy.jpg
Study Shows Effectiveness of Merakris’ Wound Care Products
June 02, 2022 07:30 ET | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- A peer-reviewed case study in the May 21 edition of SAGE Open Medical Case Reports highlights the effectiveness of two Merakris...